作者: Brian I Rini , W Kimryn Rathmell , Kimberly B Dahlman , Eric Jonasch , Benjamin G Vincent
关键词:
摘要: Predicting response to ICI therapy among patients with renal cell carcinoma (RCC) has been uniquely challenging. We analyzed patient characteristics and clinical correlates from a retrospective single-site cohort of advanced RCC receiving anti-PD-1/PD-L1 monotherapy (N = 97), as well molecular parameters in subset patients, including multiplexed immunofluorescence (mIF), whole exome sequencing (WES), T receptor (TCR) sequencing, RNA (RNA-seq). Clinical factors such the development immune-related adverse events (odds ratio (OR) 2.50, 95% confidence interval (CI) 1.05-5.91) immunological prognostic parameters, higher percentage circulating lymphocytes (23.4% vs. 17.4%, p 0.0015) lower neutrophils (61.8% 68.5%, 0.0045), correlated response. Previously identified gene expression signatures representing pathways angiogenesis, myeloid inflammation, effector presence, clear also High PD-L1 (>10% cells) low TCR diversity (≤644 clonotypes) were associated improved progression-free survival (PFS). corroborate previously published findings provide preliminary evidence clonality impacting outcome patients. To further biomarker RCC, future studies will benefit integrated analysis multiple platforms prospective validation.